Xentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Xentuzumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Xentuzumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Xentuzumab. |
| Estrone | Estrone may increase the thrombogenic activities of Xentuzumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Xentuzumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Xentuzumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Xentuzumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Xentuzumab. |
| Estriol | Estriol may increase the thrombogenic activities of Xentuzumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Xentuzumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Xentuzumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Xentuzumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Xentuzumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Xentuzumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Xentuzumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Xentuzumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Xentuzumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Xentuzumab. |
| Equol | Equol may increase the thrombogenic activities of Xentuzumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Xentuzumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Xentuzumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Xentuzumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Xentuzumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Xentuzumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Xentuzumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Xentuzumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Xentuzumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Xentuzumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Xentuzumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Xentuzumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Xentuzumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Xentuzumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Xentuzumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Xentuzumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Xentuzumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Xentuzumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Xentuzumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Xentuzumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Xentuzumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Xentuzumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Xentuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Xentuzumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Xentuzumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Xentuzumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Xentuzumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Xentuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Xentuzumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Xentuzumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Xentuzumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Xentuzumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Xentuzumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Xentuzumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Xentuzumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Xentuzumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Xentuzumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Xentuzumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Xentuzumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Xentuzumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Xentuzumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Xentuzumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Xentuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Xentuzumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Xentuzumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Xentuzumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Xentuzumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Xentuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Xentuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Xentuzumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Xentuzumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Xentuzumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Xentuzumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Xentuzumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Xentuzumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Xentuzumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Xentuzumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Xentuzumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Xentuzumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Xentuzumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Xentuzumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Xentuzumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Xentuzumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Xentuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Xentuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Xentuzumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Xentuzumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Xentuzumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Xentuzumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Xentuzumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Xentuzumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Xentuzumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Xentuzumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Xentuzumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Xentuzumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Xentuzumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Xentuzumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Xentuzumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Xentuzumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Xentuzumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Xentuzumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Xentuzumab. |